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Abstract This study was conducted to evaluate expectant
management in asymptomatic patients with an initial serum
beta-hCG titer of <2,500 IU/l and to determine the indepen-
dent ability of initial serum beta-hCG titers and trend of serum
beta-hCG to predict successful expectant management. A
cohort of patients (N0418) with suspected ectopic pregnancy
(EP) between January 1991 and July 2008 is described. Three
groups were defined: group I (n0182), immediate surgical
intervention (<24 h); group IIa (n0130), unsuccessful expec-
tant management (surgical intervention during follow-up),
and group IIb (n099), successful expectant management
(spontaneous regression of trophoblast). Hospital protocol
was not complied in 35 cases (Table 1). Beta-hCG levels
>3,000 IU/l occur in our expectant management group; how-
ever, none of these cases were successful. Unnecessary sur-
gery was prevented in 14% (n07) of asymptomatic patients
with initial beta-hCG of >2,000 IU/l. The success rate of
expectant management was 49%, without a rise in complica-
tion rate or number of acute cases. In conclusion, the initial
serum beta-hCG cutoff level of 2,000 IU/l is not a rigid upper
limit for accepting expectant management in suspected EP
and best practice is case specific. In asymptomatic patients,
the serum beta-hCG cutoff level of at least 2,500 IU/l can be
used for expectant management. This cutoff could be higher,
but interpretation is limited due to censure in follow-up
inherent to the predefined clinical protocol. There is no gain
in including patients for expectant management with initial
serum beta-hCG level >3,000 IU/l.
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Introduction
Despite the availability of accurate diagnostic algorithms for
the detection of ectopic pregnancy (EP), choosing the best
treatment when EP is suspected can still pose a dilemma in
daily practice. This dilemma arises in particular when
patients without any clinical symptoms are diagnosed with
EP. The latter tends to happen more often due to the avail-
ability of sensitive serum beta human chorionic gonadotro-
phin (beta-hCG) tests and high-resolution endovaginal
ultrasonography that allows us to detect EP in early preg-
nancy even before clinical symptoms have the chance to set
in [1, 2]. Consequently, early intervention has become a
possibility and could potentially prevent serious complica-
tions. However, a considerable number of the EPs can also
resolve spontaneously and treatment is not always necessary
[3–5]. Inherently, early detection and quick intervention
could result in overtreatment.
A recent cost analysis showed that diagnosing EP in a
single visit could potentially save around £ 1 million per
year in Scotland [6]. Because of this, the authors suggest
that diagnosis of EP should be improved and that a single
serum biomarker or other imaging modalities should be
developed. However, this could also lead to a higher rate
of overtreatment. Besides, the unnecessary exposure to risks
in overtreatment and the expenses of this treatment could
undo the gained savings. Therefore, modifications should
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ideally focus on predicting the need for future treatment
earlier in the diagnostic pathway.
Various treatments for EP have been studied, i.e., surgical
intervention (laparoscopy/laparotomy), medical treatment,
and expectant management. Expectant management has on-
ly been advised in a selective group of patients, i.e., asymp-
tomatic patients with relatively low (<2,000 IU/l) and
diminishing serum beta-hCG levels [4, 5, 7, 8]. However,
for over 10 years, asymptomatic patients with suspected EP
and an initial serum beta-hCG titer below 2,500 IU/l were
treated with expectant management. This study was
designed to evaluate this policy and to determine the inde-
pendent ability of initial serum beta-hCG titers and trend of
serum beta-hCG titers in the prediction of successful expec-
tant management.
Methods
This study describes a cohort of patients with suspected EP
between January 1991 and July 2008 at the Leiden Univer-
sity Medical Center, Leiden, The Netherlands. Suspected EP
was defined as patients with a serum beta-hCG above
1,500 IU/l and no ultrasonographic signs of intrauterine
pregnancy or patients with abdominal pain and/or blood loss
combined with a positive urine pregnancy test (i.e., beta-
hCG >50 IU) without signs of intrauterine pregnancy. Clin-
ical symptoms, ultrasonography results, and serum beta-
hCG values of these patients were registered. Patients with
a heterotopic pregnancy or medical treatment of EP were
excluded. After inclusion, patients were categorized accord-
ing to their management type: either in the group of imme-
diate treatment (within 24 h) by surgical intervention (group
I) or in the group of expectant management when follow-up
of beta-hCG and clinical signs took place (group II; Fig. 1).
Some patients in group II required surgery during follow-up
(group IIa; unsuccessful expectant management), while
others had a spontaneous regression of throphobast (group
IIb; successful expectant management).
Data analysis was performed with SPSS 16.0. Patient char-
acteristics were compared with Chi-square/Cramer’s V, except
for age, which was analyzed with one-way ANOVA. Beta-
hCG values were compared for every group combination with
the Mann–Whitney test. For the comparison of complications
between the intervention groups, patients in group I who
presented with pain were excluded because of a presumed
association between acute presentation (symptoms of acute
pain and/or peritoneal irritability objectified by the treating
physician) and higher complication rates. Furthermore, their
acute presentation was not preventable, in contrast to patients
in group IIa. For patients in group IIa, the choice to initially
refrain from surgery includes a risk of future acute presenta-
tion and thus potentially an increased risk of complications.
Therefore, patients with pain in group IIa were not excluded
for comparison of complications (Chi-square/Cramer’s V).
To compare the course of serum beta-hCG levels among
the groups, the ratio of each consecutive beta-hCG concentra-
tion to the initial concentration was calculated. The ratios in
group IIb (successful expectant management) were compared
to the ratios in the group IIa (unsuccessful expectant manage-
ment) at predetermined time points. Therefore, the ratio at the
time of surgery (group IIa) was compared to the highest ratio
during follow-up (group IIb) (independent samples t test).
The optimal beta-hCG cutoff was determined for asymp-
tomatic patients using a receiver operating characteristics
(ROC) curve. Patients with hemodynamic instability or
presenting with acute pain at initial presentation were ex-
cluded from this analysis because surgical intervention was
obliged irrespective of the serum beta-hCG values. Success
rate of expectant management was determined as the per-
centage of successes (IIb) of the total expectant management
group (II). Finally, a logistic regression model was fitted for
the probability of receiving surgery at some time during the
diagnostic pathway based on initial serum beta-hCG level
and an increase or decrease in beta-hCG between the initial
measurement and the second measurement.
Results
In the present study, 416 patients with suspected EP were
identified. Five patients with a heterotopic pregnancy were
excluded. None of the patients had medical treatment. Alto-
gether, 411 patients were included (Fig. 1), of whom 182
Fig. 1 Categorization of patients in groups according to their manage-
ment type. Group I immediate treatment (within 24 h) by surgical inter-
vention; Group IIa unsuccessful expectant management (surgery >24 h);
Group IIb successful expectant management
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patients needed surgical intervention within 24 h (group I)
because of hemodynamic instability and/or acute pain (N0
149) or a serum beta-hCG level exceeding 2,500 IU/l (N033).
Initially, 229 patients were asymptomaic and therefore eligible
for expectant management (group II). Surgical intervention
during follow-up was required in 130 patients because of no
signs of spontaneous resolution, excessive pain, or hemody-
namic instability (group IIa). In 99 patients, the EP regressed
spontaneously (group IIb). During laparoscopy, no EP could
be identified in one case (group I) which during follow-up
culminated in an intrauterine gravidity. In all other surgical
cases, EP was confirmed with pathology findings. In group
IIb, a spontaneous abortion could not be excluded in 16 cases;
however, EP remained the final diagnosis.
The distribution of the initial serum beta-hCG levels of
asymptomatic patients in the three management groups shows
that hospital protocol was not complied in 35 cases (Table 1).
One patient with an initial serum beta-hCG level of 1,809 IU/
l had a laparoscopy within 24 h because ultrasonography
showed a vital EP. And 34 patients with initial serum beta-
hCG levels above 2,500 IU/l were managed expectantly of
whom 2 (5.5%) were managed expectantly with success (se-
rum beta-hCG levels, 2,735 and 2,799 IU/L). Table 2 displays
general characteristics of the three groups. Patient character-
istics were similar, whereas initial serum beta-hCG titers dif-
fered significantly. Both intervention groups (from group I
only patients without symptoms) had a comparable number
of laparotomies and conversion rates. Neither time nor length
of surgery differed significantly. Furthermore, the incidence of
acute presentation and complication rates were similar in both
groups, except for conversion due to heavy blood loss which
occurred once in group I and not in group IIa (Table 3).
The ROC curve did not indicate an optimal trade-off be-
tween sensitivity and specificity for successful expectant man-
agement. The best trade-off reached was at a serum beta-hCG
cutoff level of 1,275.5 IU/L with a sensitivity of 65.3% and
specificity of 87.1%. None of the successful expectant man-
agement cases had an initial beta-hCG level above 3,000 IU/l,
while there were cases with an initial beta-hCG level above
3,000 in the unsuccessful group (IIa).
The calculated mean ratio, based on the highest beta-hCG
value during follow-up in group IIb, was 1.11 (99% confi-
dence interval (CI), 0.99–1.22). The mean ratio, based on
the beta-hCG value which indicated surgery in group IIa,
was 2.53 (99% CI, 1.56–3.50), which is significantly higher
(p0<.001).
Success rate of expectant management was 49%. In 14%
(n07) of the cases with an initial serum beta-hCG above
2,000 IU/l, expectant management was successful (Table 1).
However, there were also nine cases in this group who
presented with severe symptoms during follow-up and
therefore needed surgery. Of these nine cases, seven had
an initial serum beta-hCG level above 2,500 IU/l (six above
3,750 IU/l and one of 2,671 IU/l). The other two had initial
beta-hCG levels of 2,360 and 2,364 IU/l, respectively. If an
initial beta-hCG cutoff level of 2,000 IU/l had been used for
expectant management, success rate would have been 50%.
Figure 2 illustrates the estimated probabilities of eventual
surgery at a given beta-hCG level as a result of the logistic
regression model. The second visit is taken into account by
defining a dummy variable which indicates a rising (red line)
or declining (blue line) beta-hCG. The figure shows for ex-
ample that if an 80% chance of surgery is used as cutoff,
theoretically, patients with an initial serum beta-hCG level of
2,400 IU/l or higher should have surgery and patients with an
initial serum beta-hCG level below 2,400 IU/l are eligible for
follow-up. Using a cutoff of 90% certainty at the second visit,
according to this model, surgery is advised in patients with an
initial serum beta-hCG level of 2,000 IU/l or higher which is
rising, while a declining beta-hCG level under these restric-
tions could be interpreted as acceptable.
Discussion
An initial serum beta-hCG cutoff level of 2,500 IU/l for
expectant management can be used for asymptomatic patients
with suspected ectopic pregnancy. This is also suggested by a
small prospective study by Lurie et al. [9] in which patients
with rising serum beta-hCG levels were successfully managed
expectantly and a serum beta-hCG cutoff level of 2,500 IU/
l was used. However, the current protocol of the Dutch Society
of Obstetrics and Gynecology states that expectant manage-
ment is justified in asymptomatic patients with a serum beta-
hCG value until 2,000 IU/l. By raising beta-hCG cutoff from
2,000 to 2,500 IU/l in our clinic, unnecessary surgery was
prevented in 14% of the patients eligible for expectant man-
agement, while complication rates and the number of patients
with acute presentation are comparable in both intervention
groups.
Previous studies have used receiver operating character-
istics (ROC) curves to determine an optimal serum beta-hCG
cutoff level for diagnosis of EP (2,000 IU/l in asymptomatic
Table 1 Distribution of initial serum beta-hCG levels
Initial beta-
hCG titer









<2,000 1 88 92 181
2,000–2,500 0 10 5 15
>2,500 32 32 2 66
Total 33 130 99 262
Initial serum beta-hCG distribution of patients without severe pain or
hemodynamic instability in the three management groups
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patients) [1]. These studies do not consider spontaneous res-
olution of EP. We also aimed to determine an optimal serum
beta-hCG cutoff level for expectant management in asymp-
tomatic patients suspected of EP with a ROC curve. The result
shows that a serum beta-hCG cutoff level of 1,275.5 IU/L
gives the optimal trade-off between sensitivity and specificity.
However, the results of this (and other similar) ROC curve(s)
should be interpreted with caution because of the design of the
study. When serum beta-hCG levels rise above 2,500 IU/l,
patients become eligible for laparoscopy and follow-up of
serum beta-hCG concentration is censured. Although the
probability that these cases would become acute is presumed
to be very high, the true outcome remains unknown. To
determine the true optimal cutoff, ideally patients should be
managed expectantly until symptoms of acute pain and/or
peritoneal irritability arise. However, exposing patients to
such potential risks would be unethical, and thus, such a study
is unlikely to ever be done.
Table 2 Group characteristics







N 182 130 99
Age (years) a 31.9±4.8 31.4±4.4 31.7±5.5 NS
Parity b 0 (0–5) 0 (0–4) 1 (0–4) NS
Previous abortions b 0 (0–7) 0 (0–2) 0 (0–3) NS
Previous miscarriages b 0 (0–6) 0 (0–10) 0 (0–10) NS
History tubal pathology c 33 (18%) 34 (26%) 19 (19%) NS
History infertility c 44 (24%) 42 (32%) 19 (19%) NS
Amenorrhea at first visit (weeks) a 6.30±1.6 6.26±1.9 6.18±2.1 NS
Number of days till second visit a N/A 2.6±1.6 2.8±2.2 NS
Initial beta-hCG level (IU/l) d 3834 (89–100414) 1403 (58–20858) 530 (34–2799 IU/l) <.001
Observational period (days) d N/A 6.3 (2–21) 28.8 (3–95)
General characteristics of the three management groups
NS not significant, N/A not applicable
aMean ± SD
bMedian (range)
c Number of cases (percentage of intervention group)
dMean (range)
Table 3 Characteristics and complications of the intervention groups
Group I (N033) Group IIa (N0130) P Test
Immediate intervention Unsuccessful expectant
management
Laparotomiesa 4 11 NS Cramer’s V
Time surgery took place Time of surgery during the day NS Cramer’s V
Length of surgery (hh:mm)b 01:02±00:03 01:04±00:02 NS Mann–Whitney
Tubal rupture a 0 1 NS Cramer’s V
Persistent trophoblast a 0 9 NS Cramer’s V
(No decline of beta-hCG levels)
Conversions a 2 9 NS Cramer’s V
Heavy blood loss (>1 l) a 1 2 NS Cramer’s V
Conversions due to heavy blood loss a 1 0 <.05 Cramer’s V
Comparison of the characteristics and complications of the two intervention groups. As explained in the “Methods” section, only asymptomatic
patients of group I are analyzed (because of a presumed association between acute presentation and higher complication rates), whereas in group
IIa, all patients are analyzed (because an increased risk is a direct consequence of expectant management)
aN
bMean ± SD
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The success rate of expectant management in this study
was 49%. Previous studies have shown great variety in suc-
cess rates (46.7–92%) [4, 5, 8, 10]. This variety is most likely
explained by differences in inclusion criteria and protocols
used. Selection criteria for expectant management in previous
studies were much stricter. Most studies only include patients
with low and stable or decreasing serum beta-hCG levels. In
our study, patients with increasing serum beta-hCG concen-
tration were allowed to remain expectant and the cutoff level
of initial serum beta-hCGwas 2,500 IU/l, which is higher than
generally used in previous studies. Logically, a higher cutoff
level of beta-hCG will lead to a lower sensitivity explaining a
higher number of patients with an unsuccessful expectant
policy. However, this protocol also leads to a higher specificity
resulting in lower numbers of unnecessary surgery. Altogether
in this study, seven patients (14%) were spared unnecessary
surgery without observing an overall increase in complications
or acute presentation. In our opinion, this justifies the lower
success rate.
Korhonen et al. have shown a rise in serum beta-hCG in
49% of the patients requiring surgical intervention [8]. This
supports our observation in serum beta-hCG trend, i.e., increase
in beta-hCG ratio in the unsuccessful expectant group and
decrease in the successful expectant management group. In
the unsuccessful expectant management group, the mean
beta-hCG ratio at intervention was 2.5 (99% CI, 1.56–3.50),
whereas at the highest point, the mean beta-hCG ratio was 1.1
(99% CI, 0.99–1.22) in the successful expectant management
group. This finding suggests that if expectant management is
chosen for, a rise of initial beta-hCG concentration by one and a
half should be interpreted as an indication for surgical inter-
vention. Of course, the before mentioned censure in follow-up
when serum beta-hCG levels rise above 2,500 IU/l also influ-
ences this result. However, we reasoned that prolonged
follow-up of these patients would probably lead to an even
higher serum beta-hCG level. By respecting lower levels, we
are likely to stay on the safe side of the limit, but we should
keep in mind that these limits are not rigid. Table 2 illustrates
that the upper limit of our protocol was not obliged rigidly.
Serum beta-hCG levels even above 3,000 IU/l occur in our
expectant management group. However, none of these cases
were successful. Furthermore, 67% (N06) of the cases with an
initial serum beta-hCG level above 2,000 IU/l, who also de-
veloped acute symptoms during follow-up, had an initial se-
rum beta-hCG above 3,000 IU/l. This implies that there is
absolutely no gain in including patients for expectant manage-
ment when initial serum beta-hCG levels are above 3,000 IU/l.
Since EP is expensive to diagnose and exclude, mainly due
to the many assessment visits needed [6], determining the
appropriate treatment early in the diagnostic pathway could
potentially save a lot of costs. The logistic regression model
could be indicative in early decisionmaking. However, because
the model is drawn up solely from the presented cohort, con-
clusions about absolute cutoff levels cannot be made. Interpre-
tation of the calculated probabilities should be left in the hands
of the gynecologist with knowledge of the specific case. Over-
all, the model shows that an increase in serum beta-hCG level
at the second visit strongly raises the probability of having
surgery during follow-up. Although a decrease of serum beta-
hCG level at the second measurement evidently lowers the
chance of culminating into an acute surgical case, these patients
should still be observed with caution, especially in those with a
high initial serum beta-hCG level (i.e., >2,500 IU/l) who,
despite a decreasing serum beta-hCG level during follow-up,
still have a high chance of culminating into an acute situation.
This is also illustrated by the published cases of patients with
rupture of EP while serum beta-hCG level is disappearing [11,
12]. A recent study showed that a serum beta-hCG level of
>1,500 IU/l is associated with a higher rate of tubal rupture than
a beta-hCG level of <1,500 IU/l [13]. Therefore, frequent
follow-up and clear patient instructions are necessary for safe
expectant management.
Although today medical treatment with methotrexate is
gaining popularity, as it can be a good alternative for surgery,
this was not in the scope of the current study. Multiple-dose
systemic treatment with methotrexate has been shown to be as
effective as surgical treatment, whereas single-dose treatment
is less effective. However, health-related quality of life was
more severely impaired after systemic methotrexate. Further-
more, systemic multiple-dose treatment is only cost-effective
in patients with a serum beta-hCG level of <3,000 IU/l, or a
single-dose treatment in patients with a serum beta-hCG level
of <1,500 IU/l [7, 14, 15]. Because of these reasons, in some
clinics, such as the study clinic, methotrexate as treatment of
EP has not been implemented as standard treatment.
























Fig. 2 Estimated probability of surgery. The black line represents the
first visit. The red line indicates patients with a rising beta-hCG at the
second visit, and the blue line indicates patients with a declining beta-hCG
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Conclusion
The often advised initial serum beta-hCG cutoff level of
2,000 IU/l should not be handled as a rigid upper limit for
accepting expectant management in asymptomatic patients
with suspected ectopic pregnancy. However, there seems to
be no gain in including patients for expectant management
with initial serum beta-hCG levels above 3,000 IU/l. Be-
cause of the heterogeneity in patient profiles, the best treat-
ment option is case specific. Besides the clinical symptoms
and initial serum beta-hCG level, the second serum beta-
hCG measurement (i.e., rising or declining) and trend in
serum beta-hCG concentration are also very indicative for
the management choice.
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